Dabigatran for catastrophic antiphospholipid syndrome
Copyright policy )Dabigatran for catastrophic antiphospholipid syndrome
: Vitamin K antagonists (VKA) remain the treatment of choice for catastrophic antiphosphilipid syndrome (CAPS). However, when VKAs do not work for a specific patient, direct oral anticoagulants (DOAC) may be a valid therapeutic alternative. We present a patient with a psychiatric disorder and CAPS who was noncompliant to VKA and low-molecular-weight heparin. He was started on dabigatran and has remained thrombosis-free for 8 years. Due to CAPS he has developed progressive renal failure but dabigatran levels were within the expected range. In conclusion, this case report provides anecdotic evidence that dabigatran may be of use in patients with high-risk APS in whom VKA are not an option.
Male, Vitamin K, catastrophic antiphospholipid syndrome, Anticoagulants, direct oral anticoagulant, Antiphospholipid Syndrome, Dabigatran, Treatment Outcome, Humans, dabigatran, Catastrophic Illness, antiphospholipid syndrome, Factor Xa Inhibitors
Male, Vitamin K, catastrophic antiphospholipid syndrome, Anticoagulants, direct oral anticoagulant, Antiphospholipid Syndrome, Dabigatran, Treatment Outcome, Humans, dabigatran, Catastrophic Illness, antiphospholipid syndrome, Factor Xa Inhibitors
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).2 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!